Venture Kick

Clee Medical specializes in developing innovative neuroimaging and surgical access technologies to improve precision and efficiency in neurosurgery. Their products, which include imaging and sensing systems, provide enhanced access, vision, and navigation within the brain, seamlessly integrating with existing neurosurgical equipment and current surgical routines. This enables healthcare providers to potentially enhance patient outcomes with greater precision.

Lighthouse Tech specializes in designing smart eyewear frames aimed at individuals with vision impairment, blindness, and spatial perceptual disorders. Their innovative product detects obstacles above the waist and alerts users through soft haptic vibrations. The eyewear is crafted to resemble conventional frames or sunglasses, ensuring that users do not compromise on style while benefiting from enhanced safety and mobility. By combining functionality with fashion, Lighthouse Tech promotes independent outdoor navigation, ultimately fostering a greater sense of self-sufficiency and well-being for its customers.

ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.

dEEGtal’s use of AI to expedite epilepsy diagnosis could make a significant difference in patient care, by analyzing EEG data quickly, it might help identify patterns or anomalies that could be missed by human reviewers alone.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

HeroSupport is a medical device manufacturing company based in Veyrier, Geneva, established in 2019. The company specializes in creating personalized solutions that transform imaging and treatment tables into medical immobilization devices designed to enhance patient comfort during clinical procedures. By providing tailored support, these devices allow patients to receive prone breast radiotherapy without the need to adapt to the standard table setup. This innovation not only improves patient comfort but also aims to enhance the effectiveness and cost efficiency of cancer treatment for healthcare providers.

AlpineWell developing novel solutions to hunger and swallowing difficulties, AlpineWell produces patient-centric food for special medicinal purposes (FSMP) and also provides automatic nutrition tracking to detect malnutrition early on.

Transpire Bio is a biotechnology platform focused on the development of inhaled therapeutics aimed at improving global health. The company specializes in creating lower-cost generic alternatives for injectable drugs, enhancing patient access to essential medications. Its portfolio includes medicines and inhalation therapies designed for treating lung diseases as well as systemic conditions, utilizing a painless delivery method to improve patient experience and adherence to treatment. Through its innovative approach, Transpire Bio seeks to make significant advancements in the field of inhalation therapies.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Sensawear is a medical technology company that specializes in the production of wearable, textile-integrated sensors. These sensors monitor tissue oxygenation and skin pressure in real-time, alerting users to potential pressure injuries before they occur. By providing early warnings of low-oxygenation conditions caused by high-pressure points, Sensawear's products enable users to take preventative action, such as moving or being moved, thus minimizing the risk of painful and dangerous pressure ulcers.

Suri BioTech is a biotechnology company focused on developing health-promoting bacterial strains aimed at alleviating bloating and intestinal discomfort. The company specializes in creating science-based probiotics, particularly for infant health, utilizing proprietary strains that reduce hydrogen gas production by intestinal microorganisms. This innovative approach has potential applications in various functional gastrointestinal disorders, including infant colic and lactose intolerance. By leveraging its biotech platform, Suri BioTech seeks to provide effective solutions for individuals suffering from gastrointestinal issues.

Sensemodi develops an AI-powered smart wearable device that assesses joint health, particularly focusing on the knee and other joints. By utilizing a combination of thermal, acoustic, and kinematic data, the device provides a quick evaluation of joint conditions. This innovative technology aims to prevent disabilities and reduce the socioeconomic burden associated with musculoskeletal disorders. The wearable allows users to conveniently monitor their joint health, facilitating access to improved healthcare treatments and promoting proactive management of joint-related issues.

Oncobit is focused on enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. The company combines technical expertise with proprietary software and engages in close clinical collaborations, initially concentrating on melanoma while maintaining the potential to expand its solutions to other cancer types. Oncobit's innovative approach aims to improve patient outcomes by providing comprehensive and sensitive tests that enable clinics to offer tailored therapies and diagnostics, ensuring that cancer monitoring keeps pace with advancements in treatment methodologies.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

Biped.ai focuses on enhancing accessibility for blind and visually impaired individuals through its innovative smart harness. This device employs autonomous navigation technology to guide users by delivering intuitive feedback via spatial sounds and vibrations. Designed to be worn comfortably, the harness can be secured around the waist, chest, or attached to a white cane, providing an effective complement to traditional mobility aids like guide dogs and canes. Biped.ai aims to empower users by helping them detect obstacles and navigate their environments more confidently and independently.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers designed to diagnose neurological disorders. By leveraging advanced technology, Nemosia creates tracers that facilitate the early identification of neurodegenerative diseases. Their products utilize PET imaging to visualize N-methyl-D-aspartate (NMDA) receptors in the brain, allowing for timely intervention and management of neurological conditions. This innovative approach aims to enhance diagnostic capabilities and improve patient outcomes in the field of neurology.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.

Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.

Bota Systems AG, based in Zurich, Switzerland, specializes in the development and manufacture of advanced sensors for robotic applications. Incorporated in 2020, the company produces a range of products including force torque sensors, load cells, and robotic grippers designed to enhance the functionality of robotic arms, exoskeletons, prosthetic devices, and surgical platforms. Bota Systems' offerings include the Rokubi and SensONE force torque sensors, which facilitate safe and efficient interactions between robots and their environments. By providing high-quality and cost-effective components, the company aims to meet the growing demand for automation technology, enabling clients to implement integrated robotic solutions that streamline processes and improve productivity.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Aseptuva is an early-stage MedTech startup located in Technopark Winterthur, dedicated to addressing Healthcare-Associated Infections (HAI) that arise from catheter use in healthcare facilities. Catheters, essential for delivering medications, are often contaminated with pathogens, leading to severe complications such as pneumonia and bloodstream infections, which result in significant mortality and substantial healthcare costs. To combat this issue, Aseptuva is developing innovative medical devices designed for in-situ disinfection of various catheters, aiming to prevent infections before they occur. The company’s technology offers a robust automated system that assists medical staff, ultimately helping hospitals reduce the incidence of infections and save lives. Aseptuva aspires to establish a new standard in critical care, positively influencing millions of patients worldwide.

No-Touch Robotics specializes in the development and manufacturing of contactless robotic manipulators and grippers designed to handle small and fragile objects without mechanical contact. Their innovative solutions utilize electromechanical transducers and proprietary control software to manipulate, move, and monitor objects, ensuring there is no damage or contamination. This technology is particularly beneficial for automating processes that traditionally required manual handling, such as laboratory tasks in microscopy and 3D printing. By providing a safe and efficient means of object manipulation, No-Touch Robotics aims to enhance automation in various industries, addressing the needs of clients who require precision and care in handling delicate items.

CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.

XRnanotech GmbH is a Swiss deep tech company that specializes in the development and manufacturing of advanced nanotech X-ray optics designed for high-energy beams. Established in 2020 and headquartered in Untersiggenthal, the company produces a range of products, including high aspect ratio Fresnel zone plates, beam-shaping condensers for X-ray microscopy, 2D and 3D resolution test targets, gratings, and beam splitters. These innovative optics facilitate precise focusing on small samples, enabling applications in drug discovery, medical imaging, microchip inspection, and the analysis of advanced materials. XRnanotech is recognized for its commitment to delivering cutting-edge solutions that meet the needs of high-tech industries and research institutions.

Helvitek Labs, founded in 2019 and based in Lausanne, specializes in developing advanced anti-pollution face masks. The company was established by Théo-Tim Denisart, a graduate of the Swiss Federal Institute of Technology in Lausanne, and Roberto Costa, a former marketing director at Swatch, motivated by their experiences with severe air pollution in China. Helvitek Labs focuses on integrating artificial intelligence with innovative filtering and sealing technologies to improve mask comfort and effectiveness, particularly for health professionals who endure prolonged use of traditional respirators. Their efforts have garnered significant support, including recognition at the Start Lausanne contest and grants from the EPFL and the Vaud Foundation for Technological Innovation, which enabled the firm to establish itself within the EPFL Innovation Park and build a dedicated team. Officially incorporated as a public limited company in March 2020, Helvitek Labs aims to address the challenges associated with air quality and mask usage.

LifeMatrix specializes in the development of biomimetic implants and bio-engineering technology aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company creates human cell-derived, off-the-shelf tissue-engineered implants that transform into living tissue after implantation, allowing them to grow and regenerate alongside the patient. This innovative technology addresses the limitations of traditional implants and is designed to enhance patient recovery. LifeMatrix's award-winning solutions are founded on over 20 years of extensive research, supported by multiple national and international grants, and validated through more than 100 peer-reviewed publications. Preclinical studies have demonstrated the safety and efficacy of these implants, paving the way for their clinical application.

Emovo Care SA, founded in 2020 and located in Lausanne, Switzerland, develops a robotic hand orthosis aimed at individuals with motor impairments resulting from stroke. The company is ISO 13485 certified and focuses on creating accessible robotic devices that facilitate movement at home for hemiparetic stroke patients. Their flagship product is an active orthosis designed to enable users to move their hands independently, enhancing rehabilitation efforts. The device is accompanied by a mobile application that tracks usage and motivates users, thereby providing value to patients, clinicians, and health insurers. The core technology behind the orthosis emerged from research conducted during a PhD program at EPFL, which garnered significant international media attention for its innovative approach to brain-computer interfaces. The product is expected to receive CE marking by 2022.

epyMetrics AG is a Swiss health analytics company that specializes in developing diagnostic wearable solutions aimed at monitoring the body's heat balance. Incorporated in 2019 and based in Zurich, the company offers a comprehensive platform that enables users to continuously and non-invasively track their thermoregulation. Its technology detects early signs of heat stress, facilitating the prevention of heat-related accidents. The wearable device captures vital signs, including sweat rate and total sweat loss, providing crucial data that allows industries to identify the risk of heat exhaustion. By offering personalized safety benchmarks, epyMetrics aims to enhance safety protocols and reduce costs associated with heat-related incidents.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

SurgeonsLab, founded in 2020 and based in Bern, Switzerland, specializes in developing patient-specific training models for surgical procedures and the validation of new medical devices. The company focuses on microsurgical treatment planning and strategy, providing tools that enhance the training experience for medical professionals. By utilizing advanced technology, SurgeonsLab's products facilitate testing and planning for surgical interventions, significantly improving patient safety and outcomes. The company's innovative approach offers an alternative to traditional human and animal models, thereby enhancing the learning curve for medical trainees.

EarlySight SA is a Swiss company, established in 2016 and based in Lausanne, that focuses on developing innovative medical devices for the early detection and treatment of eye diseases. The company has created an advanced eye fundus camera that enhances retinal imaging through precise illumination and real-time correction of ocular aberrations. This device utilizes cellular-level imaging technology to identify subtle structural changes in the retina, allowing for effective monitoring of treatment outcomes in a quick and non-invasive manner. By facilitating the visualization of cell morphology within the retina, EarlySight aims to improve the capabilities of eye specialists in diagnosing and managing ocular conditions.

Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.

Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.

Neurosoft Bioelectronics specializes in the development of soft implantable electrodes designed to interface with the nervous system for diagnosing and treating neurological disorders. Based in Geneva, Switzerland, the company has created next-generation electrodes that are compliant and conformable, addressing the limitations of existing stiff devices. Their flagship product, SOFT ECoG, is a subdural electrode that records from and stimulates the brain's surface, enhancing recording quality and minimizing MRI artifacts. Neurosoft's technology promotes long-term bio-integration, adapting to both static and dynamic mechanics of neural tissue, which can improve therapeutic outcomes for patients and expand the applications of neural interfaces in clinical settings.

XRnanotech GmbH is a Swiss deep tech company that specializes in the development and manufacturing of advanced nanotech X-ray optics designed for high-energy beams. Established in 2020 and headquartered in Untersiggenthal, the company produces a range of products, including high aspect ratio Fresnel zone plates, beam-shaping condensers for X-ray microscopy, 2D and 3D resolution test targets, gratings, and beam splitters. These innovative optics facilitate precise focusing on small samples, enabling applications in drug discovery, medical imaging, microchip inspection, and the analysis of advanced materials. XRnanotech is recognized for its commitment to delivering cutting-edge solutions that meet the needs of high-tech industries and research institutions.

Bota Systems AG, based in Zurich, Switzerland, specializes in the development and manufacture of advanced sensors for robotic applications. Incorporated in 2020, the company produces a range of products including force torque sensors, load cells, and robotic grippers designed to enhance the functionality of robotic arms, exoskeletons, prosthetic devices, and surgical platforms. Bota Systems' offerings include the Rokubi and SensONE force torque sensors, which facilitate safe and efficient interactions between robots and their environments. By providing high-quality and cost-effective components, the company aims to meet the growing demand for automation technology, enabling clients to implement integrated robotic solutions that streamline processes and improve productivity.

C-MedTec is focused on developing a diagnostic helmet that enhances the detection and monitoring of brain concussions, addressing a critical gap in current medical practices. Traditional methods rely on subjective assessments performed by trained professionals, leaving a void in timely diagnosis and proper care. The innovative helmet measures brain metabolism and identifies abnormal neurological behavior following head trauma, facilitating early detection and diagnosis. This advancement aims to provide medical centers and sports organizations with the necessary tools to promote safer sporting practices and reduce the risk of long-term effects associated with repeated brain injuries, such as Alzheimer's disease and chronic traumatic encephalopathy (CTE).

Autonomyo is a Swiss company, founded in 2014 and based in Lausanne, that specializes in developing robotic rehabilitation solutions aimed at enhancing mobility for individuals with neurological gait disorders. The company offers a lightweight exoskeleton designed for robotically assisted gait training, which can be utilized in rehabilitation clinics as well as in home settings with remote monitoring capabilities. This technology is intended to increase accessibility and training intensity for users, enabling healthcare professionals to better support individuals with neuromuscular and motor disorders in regaining their freedom of movement. Autonomyo's team comprises engineers, developers, and healthcare professionals who are dedicated to improving the quality of life for those affected by gait impairments.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, enabling early intervention to prolong gestation and enhance neonatal health outcomes. Pregnolia serves pregnant women and gynecologists, aiming to ensure every woman experiences a happy, healthy, and informed pregnancy. The company's dedicated team, including Sabrina, Francisco, and Annette, is committed to completing clinical trials, navigating regulatory paths, and commercializing the device to support gynecologists in improving preterm birth risk assessment and management.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

Yago enables independence for people with hand motor impairments. Yago is a portable exoskeleton to support independence in daily living for people with hand motor impairments.

Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

Yago enables independence for people with hand motor impairments. Yago is a portable exoskeleton to support independence in daily living for people with hand motor impairments.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of EmbryoSpin, an innovative device designed for biochemical research. This device performs microscopic nuclear magnetic resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold, allowing for chemical analysis at the scale of a single human embryo. EmbryoSpin is engineered for robustness and user-friendliness, making it suitable for non-invasive embryo viability screening in in-vitro fertilization and various biochemical studies. The company's advancements aim to enhance medical research capabilities, particularly in the context of reproductive health.

Spectroplast AG is a Swiss company specializing in the additive printing of pure silicones, offering innovative solutions for a variety of sectors, including healthcare, wearables, industrial components, soft robotics, art, and entertainment. Founded in 2018 and based in Zurich, Spectroplast has developed a unique technology, known as SAMT, that allows for the 3D printing of industry-standard silicones with high precision and performance, without the need for molds. This process not only saves costs and time but also results in zero waste. The company provides a range of silicones with Shore hardness from A0 to A80, available in various colors and transparent options, catering to the specific needs of clients in medical and industrial applications. Through its focus on bridging cutting-edge research and market demands, Spectroplast aims to deliver customized soft material products that meet high performance and quality standards.

Viventis Microscopy is focused on developing an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples. This system includes both specialized hardware and custom microscope control software, allowing researchers to conduct extended imaging of delicate specimens such as embryos and organoids. By facilitating detailed observation of these samples, Viventis Microscopy aims to support researchers and organizations in accelerating drug development processes.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.

SwissSource Instruments specializes in the development and sale of ionization sources tailored for mass spectrometry applications. The company's technology enhances the efficiency of sample preparation, significantly increasing throughput while providing highly accurate and complex analytical results in a single step. This innovation addresses common challenges faced by researchers and industry professionals in sectors such as pharmaceuticals, food science, cosmetics, forensics, and government laboratories. By streamlining the analysis process and reducing the required sample volumes, SwissSource enables clients to effectively tackle complex sample screening, ultimately enhancing both research and operational productivity across various fields.

B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Frater.swiss specializes in the development and production of innovative devices and applications designed for out-of-hospital care, specifically targeting hypothermic patients. Their products are utilized by healthcare professionals in high-pressure environments, including emergency medicine, expedition medicine, military medicine, and veterinary medicine. The company's focus is on creating efficient solutions for measuring hypothermia and stabilizing patient temperature through warm infusion, ultimately enhancing the quality of care in critical situations. By equipping medical personnel with advanced tools, Frater.swiss aims to improve patient outcomes and facilitate life-saving interventions in emergencies.

KOVE is a MedTech company focused on enhancing fetal treatment outcomes by addressing the risks associated with fetoscopic procedures. The company has developed an innovative implantable medical device designed to close the openings created in the fetal membrane during these treatments. By securing these holes, KOVE's device helps prevent membrane rupture, which can lead to premature delivery. This advancement enables healthcare providers to perform more fetal interventions safely, ultimately aiming to improve the chances of successful outcomes for unborn children.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Prediva SA, founded in 2019 and based in Cottens, Switzerland, develops predictive machine learning software for the diagnosis and treatment of coronary artery disease. The company's innovative platform integrates medical image analysis with machine learning models and computational fluid dynamics simulations to create personalized 3D models of coronary arteries. This technology allows for the prediction of plaque progression and offers recommendations for stent placement and treatment planning. By equipping clinicians with insightful patient analyses, Prediva enables evidence-based treatment decisions that aim to reduce costs, procedure times, and the need for invasive interventions.

Readily3D is a Swiss company based in Lausanne, specializing in volumetric 3D printing solutions. Founded in 2020 as a spin-off from the École Polytechnique Fédérale de Lausanne (EPFL), the company has developed innovative printers capable of producing complex, patient-specific devices in under 30 seconds using tomography. Their technology utilizes a liquid photosensitive polymer, which is cured through dynamic light patterns from multiple angles, allowing for the creation of tailored orthoses for patients with hearing loss and surgical models for medical professionals. This approach not only enhances patient care but also streamlines surgical planning, positioning Readily3D as a leader in the advancement of personalized medical devices.

Hemolytics is a MedTech company focused on advancing malaria detection through the development of a medical diagnostic device. This innovative device utilizes a chemical amplification method to enhance the sensitivity of malaria detection, achieving a level ten times greater than existing malaria rapid diagnostic tests. By amplifying a pan-malarial biomarker with stable and inexpensive reagents, Hemolytics aims to provide a point of care test that allows for the early detection of malaria, ultimately improving patient outcomes and facilitating timely treatment.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Auxivo AG is a company based in Zürich, Switzerland, specializing in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing strain and fatigue, Auxivo's exoskeletons enhance worker safety and overall well-being, helping to prevent injuries and improve productivity in the workplace. The company's focus on creating accessible and effective solutions aims to ensure that workers can perform their duties with greater ease and security.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.

ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in the development of non-invasive assays aimed at the screening, diagnosis, and monitoring of cancer. The company's initial product is a urine assay designed specifically for the screening of prostate cancer, reflecting its commitment to advancing cancer detection methods. Through its innovative approaches, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Viventis Microscopy is focused on developing an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples. This system includes both specialized hardware and custom microscope control software, allowing researchers to conduct extended imaging of delicate specimens such as embryos and organoids. By facilitating detailed observation of these samples, Viventis Microscopy aims to support researchers and organizations in accelerating drug development processes.

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Touchless Automation GmbH is a high-tech company based in Biel/Bienne, Switzerland, specializing in the production of contactless handling equipment for the manipulation, assembly, and inspection of small components, particularly in the optoelectronic, MEMS, and micro-optical sectors. Founded in 2016, the company offers innovative solutions such as Levio, an automatic die sorter that efficiently picks up components from adhesive tapes, and Paradigma, a platform designed for pick and place operations without physical contact. Their technology is applicable across various industries, including aerospace, semiconductor, optoelectronics, luxury watches, microsystems, and medtech, facilitating processes such as inspection, sorting, palletizing, and assembly. Touchless Automation's systems enable the handling of components ranging from 0.1 to 20 millimeters, significantly enhancing production yield and operational efficiency.

Prediva SA, founded in 2019 and based in Cottens, Switzerland, develops predictive machine learning software for the diagnosis and treatment of coronary artery disease. The company's innovative platform integrates medical image analysis with machine learning models and computational fluid dynamics simulations to create personalized 3D models of coronary arteries. This technology allows for the prediction of plaque progression and offers recommendations for stent placement and treatment planning. By equipping clinicians with insightful patient analyses, Prediva enables evidence-based treatment decisions that aim to reduce costs, procedure times, and the need for invasive interventions.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of EmbryoSpin, an innovative device designed for biochemical research. This device performs microscopic nuclear magnetic resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold, allowing for chemical analysis at the scale of a single human embryo. EmbryoSpin is engineered for robustness and user-friendliness, making it suitable for non-invasive embryo viability screening in in-vitro fertilization and various biochemical studies. The company's advancements aim to enhance medical research capabilities, particularly in the context of reproductive health.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in the development of non-invasive assays aimed at the screening, diagnosis, and monitoring of cancer. The company's initial product is a urine assay designed specifically for the screening of prostate cancer, reflecting its commitment to advancing cancer detection methods. Through its innovative approaches, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.

Viventis Microscopy is focused on developing an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples. This system includes both specialized hardware and custom microscope control software, allowing researchers to conduct extended imaging of delicate specimens such as embryos and organoids. By facilitating detailed observation of these samples, Viventis Microscopy aims to support researchers and organizations in accelerating drug development processes.

CorasMedical is the development, production and sale of medical devices. It may set up branches and agencies at home and abroad, set up subsidiaries, participate in other ventures, acquire, manage and dispose of intellectual property and real estate, and enter into all business and contracts that directly or indirectly promote the purpose of the Company or which concern the investment and management of the Company's assets.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Touchless Automation GmbH is a high-tech company based in Biel/Bienne, Switzerland, specializing in the production of contactless handling equipment for the manipulation, assembly, and inspection of small components, particularly in the optoelectronic, MEMS, and micro-optical sectors. Founded in 2016, the company offers innovative solutions such as Levio, an automatic die sorter that efficiently picks up components from adhesive tapes, and Paradigma, a platform designed for pick and place operations without physical contact. Their technology is applicable across various industries, including aerospace, semiconductor, optoelectronics, luxury watches, microsystems, and medtech, facilitating processes such as inspection, sorting, palletizing, and assembly. Touchless Automation's systems enable the handling of components ranging from 0.1 to 20 millimeters, significantly enhancing production yield and operational efficiency.

SwissProsthetics is a MedTech company based in Zurich, Switzerland, specializing in the development of 3D printed prosthetic hands for children and adults with upper limb loss. The company's innovative prostheses feature a modular design, consisting of a shaft that connects to various hand modules tailored for specific activities, such as biking, swimming, and skiing. This modularity allows for an affordable and robust solution, while the fitting process is user-friendly and does not require a specialist, enabling users to engage in daily activities with ease.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Rapid Graft is a medical device company founded in 2018 and based in Zurich, Switzerland. The company specializes in developing an innovative dermatome designed to facilitate the precise and rapid harvesting of small split-skin grafts. This technology aims to enhance the treatment of chronic wound patients and address future needs in tissue engineering. The device enables surgeons to perform skin grafting procedures with minimal discomfort, eliminating the need for specialist intervention or an operating room. Additionally, it reduces the risk of infection and scarring, promoting faster skin cell regeneration and improved healing outcomes for patients.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

Nanoleq AG, established in 2017 and based in Zurich, Switzerland, specializes in the development and manufacturing of innovative electric cables using stretchable electronics. As a spinoff from ETH Zurich, the company focuses on integrating electronic functionalities into textiles, particularly for health monitoring. Its products utilize advanced conductive silicone technology to create soft sensors capable of recording vital signs such as heartbeat, electrocardiograms, and breathing patterns through comfortable and washable garments. These sensors are designed for various applications, including healthcare, sports, and workwear, with the aim of setting a standard in the health-monitoring textile market. Nanoleq is committed to facilitating the rapid development and widespread adoption of smart textiles across multiple sectors, including robotics and aerospace.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Dicronis GmbH, founded in 2018 and based in Monteggio, Switzerland, specializes in developing microneedles for diagnostic and therapeutic applications. The company's primary product, Lymphit, is a wearable device designed to monitor lymphatic function, allowing for safe and scalable home-based use. Lymphit aims to facilitate the early diagnosis of secondary lymphedema, a potential complication of various cancer treatments. By enabling remote monitoring of lymphatic activity, the device empowers healthcare providers to diagnose conditions prior to the onset of swelling and to evaluate the most effective conservative treatments. This innovative approach not only enhances patient quality of life but also offers significant benefits to the healthcare system by optimizing treatment strategies and potentially reducing costs.